Thus, PD-L1-positive NSCLC is associated with enhanced response to anti-PD-L1/PD-1 immunotherapy.[32] Meanwhile, the high-risk LUAD patients showed significantly higher expression of the T-effector and interferon-γ gene signature than the low-risk patients (P < .05). This evidence concerns the gene CD274 and non-small cell lung carcinoma.